Recursion Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
28/02/2025 14:32
Recursion Pharmaceuticals Inc RXRX.OQ reported a quarterly adjusted loss of 53 cents per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -42 cents. The mean expectation of eight analysts for the quarter was for a loss of 43 cents per share. Wall Street expected results to range from -70 cents to -36 cents per share. Revenue fell 58.6% to $4.51 million from a year ago; analysts expected $19.04 million. Recursion Pharmaceuticals Inc's reported EPS for the quarter was a loss of 53 cents. The company reported a quarterly loss of $178.91 million. Recursion Pharmaceuticals Inc shares had risen by 13.5% this quarter. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 1.2% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "hold" Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $10.00 This summary was machine generated from LSEG data February 28 at 02:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Dec. 31 2024 | -0.43 | -0.53 | Missed |
| Sep. 30 2024 | -0.35 | -0.34 | Beat |
| Jun. 30 2024 | -0.40 | -0.40 | Met |
| Mar. 31 2024 | -0.42 | -0.39 | Beat |
Recent news on Recursion Pharmaceuticals
See all newsBrief: Tempus And Recursion Extend Existing Data License Agreement And Enter New License Agreement For Recursion’S RNA Foundation Model
Brief: Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026 - SEC Filing
Recursion Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Recursion Pharmaceuticals Q2 revenue misses estimates, cuts 2026 expense outlook
Brief: Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million